- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03517995
Randomized, Phase II Clinical Trial of Sulforaphane in Bladder Cancer Chemoprevention
The main purpose of this study is to see if Prostaphane is effective and can help reduce the progression of bladder cancer. Researchers also want to find out if Prostaphane is safe and tolerable, and to evaluate how Prostaphane works to reduce the progression of bladder cancer. This study will compare Prostaphane with a placebo to see if taking Prostaphane is better than taking a placebo. A placebo is a pill that looks like Prostaphane but has no drug or other active ingredients in it.
The study will be presented to eligible patients by the patient's surgeon at the time when an appointment is made for cystoscopy for suspicion of bladder cancer (BC) or to confirm BC diagnosis.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study will be presented to eligible patients by the patient's surgeon at the time when an appointment is made for cystoscopy for suspicion of bladder cancer (BC) or to confirm BC diagnosis.
Participants will be asked to spend 21 to 30 days in this study. The study will be conducted during the time from when the participant is diagnosed with bladder cancer to when they undergo a surgical procedure for the treatment or removal of their bladder cancer. The surgical procedure is done as a part of their regular medical care. Participants will be asked to come for 1 additional visit as part of this research study at the midpoint between their biopsy and surgery.
Study Type
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Florida
-
Tampa, Florida, United States, 33612
- H. Lee Moffitt Cancer Center and Research Institute
-
Tampa, Florida, United States, 33612
- James A. Haley Veteran's Administration Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men and women; age ≥18 years; evidence of non-muscle invasive or muscle invasive primary bladder tumor (urothelial carcinoma +/- variant histology) discovered on cystoscopy or radiologic imaging performed within 60 days of randomization; with no evidence of distant metastases; planned Transurethral Resection+B21 (TURBT), cystoscopy with biopsies or cystectomy (total or partial);
- Absent prior pelvic radiation; normal organ function;
- Absent neoadjuvant chemotherapy (refusal or ineligibility); (the participant may have prior intravesical treatment exposure (including Bacillus Calmette-Guerin (BCG), mitomycin, gemcitabine, valrubicin, docetaxel, etc.) for bladder cancer (BC) (excluding primary bladder radiation therapy) provided that treatment was completed greater than 30 days prior to the patient's randomization visit);
- Non-smokers (urinary cotinine tested);
- Agree to restrict dietary sources of Sulforaphane (SFN) to 3 or 5 servings/week and abstain from consuming SFN supplements beginning three days prior to start of study and throughout duration of the study;
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2;
- Willing to discontinue current vitamin/mineral supplement use and substitute with a standard multivitamin supplement provided for the study;
- Willing to use an effective method of contraception, if the partner is of child-bearing age, while on study;
- Willing to comply with proposed visit and treatment schedule;
- Able to understand and willing to sign a written informed consent document;
- Participants must have normal organ and marrow function.
Exclusion Criteria:
- Evidence of other cancers (excluding non-melanoma skin cancer) or metastatic disease;
- Prior pelvic radiation; concurrent systemic chemotherapy for any other cancer, excluding non-melanoma skin cancer;
- Any treatment for the bladder tumor other than intravesical therapy;
- Prior treatment with a known histone deacetylase inhibitor (including but not limited to valproic acid, suberoylanilide hydroxamic acid (SAHA), Panobinostat (LBH589), etc.) within 6 months prior to starting study treatment or while on study therapy;
- Current treatment with warfarin;
- Use of dietary supplements or herbal remedies which may affect the study outcome - unless the participant is willing to discontinue taking them for 1 month prior to starting study;
- Usual consumption of > 5 servings per week of brassica vegetables;
- Gastrointestinal ailments which would interfere with the ability to adequately absorb SFN;
- Allergy/known intolerance to cruciferous vegetables;
- Used antibiotics (more than 3 doses) within 10 days prior to study (day -14 prior to study randomization);
- Current smoker.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Sulforaphane Plus Surgery
Sulforaphane Administration prior to bladder cancer surgery.
|
1 capsule (10 mg Prostaphane) taken two times per day (2 capsules, 20 mg Prostaphane total).
Other Names:
The study will be conducted during the time from when participants are diagnosed with bladder cancer to when they undergo a surgical procedure for the treatment or removal of their bladder cancer.
The surgical procedure is done as a part of their regular medical care.
Other Names:
|
Placebo Comparator: Placebo Plus Surgery
Placebo Administration prior to bladder cancer surgery.
|
The study will be conducted during the time from when participants are diagnosed with bladder cancer to when they undergo a surgical procedure for the treatment or removal of their bladder cancer.
The surgical procedure is done as a part of their regular medical care.
Other Names:
1 capsule (placebo) taken two times per day (2 capsules total).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Magnitude of Change
Time Frame: Up to 30 days
|
Magnitude of change in Intermediate Endpoint Biomarkers (IEBs) of proliferation (Ki-67 expressing cells- an independent marker of poor prognosis in bladder cancer (BC)) from baseline to end of treatment with 20 mgs Prostaphane® [Nutinov Labs, France] containing 200 μmol of Sulforaphane (SFN) a day at 3-4 weeks (maximum 30 days) in BC cells and benign/adjacent cells.
|
Up to 30 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Effectiveness of Sulforaphane vs. Placebo
Time Frame: End of study, approximately 30 days
|
Effectiveness of SFN at this dose (vs.
placebo) as indicated by modulation of other IEBs of proliferation, apoptosis and phase II enzymes, as well as the potential molecular mechanism of SFN, we will measure changes in: (i) BC histology grade; (ii) labeling index of a sensitive biomarker that is a member of DNA replication origin licensing complex, Mcm2; (iii) apoptosis (Caspase-3); (iv) Phase II enzymes (glutathione transferases, epoxide hydrolase, Nicotinamide adenine dinucleotide phosphate (NAD(P)H): quinone reductase, and glucuronosyltransferases); (v) Nrf2 and Transcription factor (NF-kB) signaling, from baseline to end of treatment in BC cells and benign/adjacent cells.
|
End of study, approximately 30 days
|
Occurrence of Adverse Events per Study Arm
Time Frame: End of study, approximately 30 days
|
Safety of SFN at this dose (vs.
Placebo) as indicated by incidence of adverse events and toxicities, monitored using Common Toxicity Criteria version 5.0, complete blood count (CBC), and complete metabolic panel (CMP) from baseline at mid-point and at end of trial.
|
End of study, approximately 30 days
|
Mid-study Bioavailability of Sulforaphane
Time Frame: Mid-study, approximately 15 days
|
Bioavailability, of SFN at this dose vs. Placebo.
Investigators will measure change in SFN in plasma and bladder tissue from baseline, at mid-point and at end of study.
|
Mid-study, approximately 15 days
|
End of Study Bioavailability of Sulforaphane
Time Frame: End of study, approximately 30 days
|
Bioavailability, of SFN at this dose vs. Placebo.
Investigators will measure change in SFN in plasma and bladder tissue from baseline, at mid-point and at end of study.
|
End of study, approximately 30 days
|
Adherence of Sulforaphane vs. Placebo
Time Frame: End of study, approximately 30 days
|
Adherence based on pill counts and diet and pill logs from baseline.
|
End of study, approximately 30 days
|
Acceptability of Sulforaphane vs. Placebo
Time Frame: End of study, approximately 30 days
|
Acceptability based on pill counts and diet and pill logs from baseline.
|
End of study, approximately 30 days
|
Collaborators and Investigators
Investigators
- Principal Investigator: Nagi Kumar, Ph.D, H. Lee Moffitt Cancer Center and Research Institute
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MCC-19574
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bladder Cancer
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedStage III Bladder Cancer | No Evidence of Disease | Stage II Bladder Cancer | Stage IVA Bladder Cancer | Stage IVB Bladder CancerUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteCompletedMuscle-Invasive Bladder Carcinoma | Bladder Cancer Stage II | Bladder Cancer Stage III | Bladder Cancer Stage IVUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)WithdrawnRecurrent Bladder Cancer | Urinary Complications | Stage 0 Bladder Cancer | Stage I Bladder Cancer | Stage II Bladder Cancer
-
National Cancer Institute (NCI)CompletedStage III Bladder Cancer | Stage I Bladder Cancer | Stage II Bladder CancerUnited States
-
National Cancer Institute (NCI)TerminatedStage III Bladder Cancer | Stage IV Bladder Cancer | Recurrent Bladder Carcinoma | Bladder Adenocarcinoma | Bladder Squamous Cell Carcinoma | Bladder Urothelial Carcinoma | Stage I Bladder Cancer | Stage II Bladder CancerUnited States
-
Fox Chase Cancer CenterTerminatedStage III Bladder Cancer | Distal Urethral Cancer | Proximal Urethral Cancer | Squamous Cell Carcinoma of the Bladder | Urethral Cancer Associated With Invasive Bladder Cancer | Stage II Bladder CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedStage III Bladder Cancer | Stage IV Bladder Cancer | Recurrent Bladder Carcinoma | Stage II Bladder CancerUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Bristol-Myers SquibbRecruitingUrinary Bladder Cancer | Invasive Bladder CancerNetherlands
-
Taris Biomedical LLCBristol-Myers SquibbTerminatedBladder Cancer TNM Staging Primary Tumor (T) T2 | Bladder Cancer TNM Staging Primary Tumor (T) T2A | Bladder Cancer TNM Staging Primary Tumor (T) T2B | Bladder Cancer TNM Staging Primary Tumor (T) T3 | Bladder Cancer TNM Staging Primary Tumor (T) T3A | Bladder Cancer TNM Staging Primary Tumor... and other conditionsUnited States
-
Baylor College of MedicinePfizerTerminatedBladder Cancer | Invasive Bladder Cancer | Metastatic Bladder CancerUnited States
Clinical Trials on Sulforaphane Administration
-
Johns Hopkins UniversityTemple University; State University of New York at BuffaloCompleted
-
University of OxfordQuadram Institute BioscienceRecruitingObesity | Metabolic Syndrome | Non-Alcoholic Fatty Liver DiseaseUnited Kingdom
-
Second Affiliated Hospital, School of Medicine,...UnknownAlzheimer DiseaseChina
-
Andrew ZimmermanJohns Hopkins UniversityCompleted
-
John KirkwoodCompletedMelanoma | Atypical NeviUnited States
-
Central South UniversityStanley Medical Research InstituteCompleted
-
Xiangya Hospital of Central South UniversityUnknownFrontal Lobe Dysfunction
-
Johns Hopkins UniversityRecruitingSkin AgingUnited States
-
Karolinska InstitutetLantmännenCompletedDiabetes Mellitus, Type 2 | Chronic Kidney Disease stage4 | Chronic Kidney Disease Stage 3BSweden
-
Anders Rosengren, MD PhDCompletedDiabetes Mellitus, Non-Insulin-Dependent